Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
A6NNB3
UPID:
IFM5_HUMAN
Alternative names:
Bone-restricted interferon-induced transmembrane protein-like protein; Dispanin subfamily A member 1
Alternative UPACC:
A6NNB3
Background:
Interferon-induced transmembrane protein 5, also known as Bone-restricted interferon-induced transmembrane protein-like protein and Dispanin subfamily A member 1, plays a crucial role in bone mineralization. This protein's involvement in the biological process is essential for maintaining bone strength and integrity.
Therapeutic significance:
Osteogenesis imperfecta 5, a condition marked by bone fragility and susceptibility to fractures, is directly associated with mutations in the gene encoding this protein. Understanding the role of Interferon-induced transmembrane protein 5 could open doors to potential therapeutic strategies for managing and treating this debilitating disease.